We currently have one approved medication on the market, as well as a number of late-stage and pre-clinical programs in our pipeline.
View our pipelineAdverse events should be reported. Please report to your country competent authority.
To report negative side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).
If you are a UK health care professional, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Immunocore, through the channels below.
United States:
medical.information@immunocore.com
844-IMMUNO1
Europe/Rest of World:
medinfo.eu@immunocore.com
+442076645100 (European local toll)
+00 800-74451111 (toll-free)
KIMMTRAK in the United States
KIMMTRAK (tebentafusp-tebn)
(Injection for Intravenous Use 100 mcg/0.5 mL)
KIMMTRAK in the United Kingdom
KIMMTRAK (tebentafusp)
(Concentrate for Solution for Infusion 200 mcg/mL)
KIMMTRAK in Europe
KIMMTRAK (tebentafusp)
(Concentrate for Solution for Infusion 100 mcg/0.5 mL)
KIMMTRAK in Switzerland
KIMMTRAK (tebentafusp)
(Concentrate for Solution for Infusion 100mcg/0.5mL)